please answer

Professor Burke asserts that when molecular biomarkers for disease are established CDSS will become more accurate in facilitating diagnoses. The four leading causes of Death in the US are: 1) Heart disease, 2) Cancer, 3) Unintentional Injury (accidents) and 4) Chronic Lung disease. Heart Disease has known biomarkers of increased risk, e.g. high cholesterol values. Lowering cholesterol reduces, but does not eliminate risk. Lowering cholesterol with medications has been shown to reduce deaths in formal studies. Changing diet and exercising, the most common recommended strategy, has not been studied in similar formal interventional trials. There are no known pathonymonic biomarkers. Cancer is a diverse group of diseases, primarily classified by the tissue of origin. Lung and colorectal cancer are leading cancer causes of death for men and women. Prostate cancer is also a leading cause of death in men, but obviously not women. Breast cancer is a leading cause of death in women. While men can have breast cancer it is not a predominant cause of death in men. There is no biomarker for Fatal Injuries, the 3rd leading cause of death. There are over 20 candidates for Chronic Lung Disease biomarkers, some of which require Bronchoalveolar Lavage Fluid for testing. None is pathonymonic. Write a 1-2 page reflection on the role CDSS could or should have in improving the value and reducing the error rate in healthcare. Recall that reducing misdiagnosis is a legitimate quality improvement. Al within this context is fair game. Reference any sources you use